|

INV-8989 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Shenzhen Ionova Life Sciences Co., Ltd.1

Indications

  • Biliary Cancers1
  • Colon and Rectal Cancer1
  • Advance Solid Tumors1
  • Pancreatic Adenocarcinoma Advanced or Metastatic1
  • Non-small Cell Lung Cancer (NSCLC)1

Other1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.